Author's posts
Coherus BioSciences And Mark Cuban’s Drug Company Aim To Disrupt Humira-Referenced Biosimilar Space With Launch Of Yusimry At A 85% Discount
Coherus BioSciences and Mark Cuban’s Cost Plus Drug Company will shake up the Humira and Humira-referenced biosimilar space with the launch of Yusimry at a 85% discount.
Coherus BioSciences And Mark Cuban’s Drug Company Aim To Disrupt Humira-Referenced Biosimilar Space With Launch Of Yusimry At A 85% Discount
Coherus BioSciences and Mark Cuban’s Cost Plus Drug Company will shake up the Humira and Humira-referenced biosimilar space with the launch of Yusimry at a 85% discount.
Pharmaceutical Industry Ought To Justify Drug Prices On Value, Not R&D Costs
Sometimes a lot of R&D goes into only marginally effective drugs. Other times, drugs with relatively minimal amounts of R&D turn out to have a lot of value.
UnitedHealthcare Will Soon Implement A Controversial Prior Authorization Policy For Surveillance And Diagnostic Colonoscopies
On June 1st, UnitedHealthcare will implement a controversial prior authorization policy for surveillance and diagnostic colonoscopies.
America’s Gun Violence Is A Public Health Emergency, But Politics And The Courts Prevent A Proper Response
Gun violence is a leading cause of premature death in the U.S. In 2021, more than 48,000 Americans died from guns. Repeated attempts to introduce gun control measures have run into formidable opposition in the U.S. Congress as well as the judiciary.
PBM Reform Legislation May Be One Step Closer To Reality, But It’s Missing Two Key Components
Given the agreement on PBM reform across a disparate group of stakeholders, perhaps the two missing components in the proposed legislation – pass-through to patients and delinkage of PBM rebates and fees from list prices – will eventually find a way to…
FDA Moves One Step Closer To Switching An Oral Contraceptive From Prescription-Only To Over-The-Counter Status
Today, the FDA moved one step closer to approving the first OTC birth control pill in the US. Perrigo had applied for a switch from prescription-only to OTC status for its once-daily oral contraceptive named Opill. FDA could reach a final decision on t…
As Ads For Sports Betting Proliferate In U.S., Europe Clamps Down Due To Potential Risk Of Compulsive Gambling
Ads for gambling blanket the airwaves and social media sites. While the U.S. advertising blitz is in full swing, many nations in Europe are moving to place strict limits on promotions or abolish betting ads altogether.
Donanemab’s Data Look Promising, But It Won’t Lead To An Imminent Change In Medicare’s Severe Restrictions On Coverage Of Alzheimer’s Disease Biologics
Until lecanemab and donanemab are granted regular FDA approval it’s very unlikely there will be a change in CMS’s current severely restrictive coverage policy. Once approved CMS will be inclined to relax coverage limits. This said, upon approval unfett…
Donanemab’s Data Look Promising, But It Won’t Lead To An Imminent Change In Medicare’s Severe Restrictions On Coverage Of Alzheimer’s Disease Biologics
Until lecanemab and donanemab are granted regular FDA approval it’s very unlikely there will be a change in CMS’s current severely restrictive coverage policy. Once approved CMS will be inclined to relax coverage limits. This said, upon approval unfett…
